RxDoctor Payments Data

Jeffrey Bernstein, MD

Cardiovascular Disease · New Hyde Park, NYNPI 1700821766

Payments from drug & device makers

$1,386in general payments, 2019–2025

Across 77 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$222
  • Astellas Pharma US Inc$158
  • Amarin Pharma, Inc.$121
  • Merck$120
  • Johnson & Johnson$116
  • Amgen$107
  • plus $542 from 14 others

What the payments were for

  • Food & beverage$1,386100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,386 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$236,572
Medicare patients
555
Services billed
2,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$261,132
XareltoRivaroxaban57$82,940
EntrestoSacubitril/Valsartan44$68,031
JardianceEmpagliflozin19$28,636
Repatha SureclickEvolocumab26$24,900
FarxigaDapagliflozin Propanediol12$18,406
Metoprolol Succinate320$5,827
Rosuvastatin Calcium387$5,033
Atorvastatin Calcium482$4,318
Losartan Potassium364$3,800
Amlodipine Besylate457$2,641
Ezetimibe81$1,810
Bumetanide23$1,401
Irbesartan42$1,365
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide100$1,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$261,132192 claims
Johnson & JohnsonXarelto$116$82,94057 claims
NovartisEntresto$74$68,03144 claims
Boehringer IngelheimJardiance$24$28,63619 claims
AstraZenecaFarxiga$21$18,40612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →